Evolving Treatment Approaches in EGFR- Mutated NSCLC: First-Line Therapies and AE Management

Dr. Husain discusses how updated MARIPOSA and FLAURA-2 data highlight the growing role of combination regimens in improving both systemic and CNS outcomes for patients with EGFR-mutant NSCLC.

Dr. Husain discusses how selecting between FLAURA-2, MARIPOSA, and other frontline regimens requires balancing efficacy, safety, and sequencing considerations to deliver the most personalized care in EGFR-mutant NSCLC.

Dr. Husain discusses how anticipating resistance mechanisms and tailoring post-progression strategies based on initial therapy are key to optimizing sequencing in EGFR-mutant NSCLC.